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Objective: Probiotics and nutrient intakes modulate gastrointestinal (GIT) microbiota and symptoms of irritable bowel syndrome
(IBS). The extent to which these factors influence the microbiota is relatively unknown. The primary objective of this paper was to
investigate the effect of a probiotic on gut microbiota and IBS symptoms. The secondary objective was exploring correlations
between dietary intake and gut microbiota.
Design: This study was an extension of a randomised clinical trial (Clinical Trials Registry NCT018867810). Dietary intake was
recorded by three-day estimated food records. Faecal samples were collected at three time points: (1) baseline (A), (2) after
eight weeks’ probiotic supplementation (Lactobacillus plantarum 299v) (B) and (3) following a two-week washout period (C).
Total Bacteroides spp., Bifidobacteria bifidum and Lactobacillus plantarum were quantified by quantitative real-time
polymerase chain reaction (qPCR).
Results: Twenty-eight diarrhoea-predominant IBS (D-IBS) and 24 constipation-predominant IBS (C-IBS) patients participated.
Lactobacillus plantarum profiles at baseline (A) were significantly different between C-IBS and D-IBS (−0.956 ± 1.239 vs.
−1.700 ± 1.239; p = 0.024). There was no significant change in bacterial counts after completion of the trial (B) and following
the washout period (C) between groups. In both groups there were significant direct correlations between fibre and
Lactobacillus plantarum and inverse correlations between fibre and Bacteroides spp. There was no difference in symptom
severity scores between treatment and placebo groups during the study.
Conclusion: The probiotic had no effect on symptoms and GIT microbiota. Certain nutrients strongly correlate to certain
bacterial profiles, suggesting that nutrients can significantly influence gastrointestinal microbiota composition.
Keywords: diet, gut microbiota, irritable bowel syndrome, probiotic
Introduction
Irritable bowel syndrome (IBS) is the most prevalent functional
gastrointestinal (GI) disorder and is estimated to affect one in
five people.1 No specific test exists for the confirmation of IBS
and the diagnosis is dependent on the ROME criteria, which
are symptom based. Symptoms include abdominal pain or dis-
comfort, irregular bowel movements, flatulence and consti-
pation or diarrhoea. According to the proportion of
symptomatic stools, IBS can further be divided into diarrhoea
predominant (D-IBS), constipation predominant (C-IBS), mixed
(M-IBS) or unclassed (U-IBS).2–4 Various pathogenic mechanisms
have been proposed for IBS including visceral hypersensitivity,
abnormal motor function, low-grade mucosal inflammation,
food intolerance and altered GI microbiota, as well as psychoso-
cial and genetic factors.5 However, the pathogenesis of IBS
remains poorly understood.
Current treatment regimens for IBS are mainly symptom based.
From the early days, diet has formed the cornerstone of IBS man-
agement, especially high-fibre diets. More recently, multiple ran-
domised controlled trials have shown that the low-fermentable
oligo-, di-, mono-saccharides, and polyols (FODMAP) diet is ben-
eficial for the improvement of overall and individual symptoms
in IBS.6 A number of recent systematic reviews and meta-
analyses suggest that probiotics are associated with an improve-
ment in IBS symptoms compared with placebo. However, these
results should be interpreted with caution, given the methodo-
logical limitations of the contributing studies.7–10 Probiotic treat-
ments are routinely recommended in clinical practice to alter
gut microbiota, as dysbiosis has been confirmed in IBS
patients.11 The treatment outcomes with these modalities are
disappointing, with high failure and recurrence rates and high
economic cost.12 Seemingly, a more structured approach to
IBS care is needed.
The human GI microbiota constitutes a complex ecosystem that
is beneficial to the host under normal conditions.13 GI infection
or administration of antibiotics perturbs GI microbiota compo-
sition and has been linked to the expression of dysfunctional
GI symptoms.14 Several studies over recent years have demon-
strated compositional differences in the intestinal microbiota
between IBS and healthy controls.15–17 In general, data indicate
that the overall microbial diversity of the intestinal microbiota in
IBS is reduced compared with the diversity in healthy individ-
uals.15,18,19 There is a rationale for targeting the intestinal micro-
biota in the treatment of IBS.20
The link between diet, microbiota and fermentation products
might have an essential role to play in IBS aetiology.15 Few
studies have examined the impact of dietary interventions on
the microbiota in IBS patients. A low-FODMAP diet has been
linked to reduced Bifidobacteria counts,21 which seems a
paradox given their potential symptom benefit.
There have been relatively few randomised controlled trials
(RCTS) that have assessed the effects of a probiotic on IBS symp-
toms and GI microbiota.22 To an even lesser degree, barring the
FODMAP studies, the relationship of nutrient intakes on GI
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microbiota is poorly understood in IBS. Whether a disease-prone
microbial composition can be transformed into a healthier com-
position by a probiotic or is influenced by diet to improve
patient sense of well-being remains fundamentally an unan-
swered question. The aim of the present study was to investigate
the effect of a probiotic supplement, L. plantarum 299v, on the (i)
faecal microbiota and (ii) GI symptoms of IBS and, second, to
investigate correlations between dietary intake and faecal
microbiota.
Materials and methods
Subjects
A total of 52 IBS subjects participated in this study, which formed
a part of a larger probiotic RCT (Clinical Trials Registry number
NCT01886781) evaluating the efficacy of an eight-week treat-
ment regime of Lactobacillus plantarum 299v for IBS.23 The
study was approved by the Health Research Ethics Committee
at Stellenbosch University (N10-08-270) and written informed
consent to participate was obtained from each participant on
enrolment. Twenty-four C-IBS and 28 D-IBS patients were
included after screening by a gastroenterologist and recruited
according to the study inclusion criteria and their willingness
to participate. Detailed methodology followed was discussed
in a paper by Stevenson et al.23
Probiotic intervention
The RCT was 12 weeks in duration, with a two-week run-in
phase, then active treatment for eight weeks, followed by a
two-week washout period. During the intervention, all subjects
received either L. plantarum 299v or placebo (once daily). Pro-
biotic treatment was given to 19 D-IBS patients and 16 C-IBS
patients while 17 patients from both groups received placebo.
The test product contained 5 × 109 colony forming units (CFU)
of L. plantarum 299v and it was tested against placebo capsules,
filled with micro-crystalline cellulose powder (mean content of
cellulose per capsule 256 mg), of identical taste, texture and
appearance by the manufacturer (Ferlot Manufacturing and
Packaging (PTY) Ltd, Jeffreys Bay, South Africa). The test
product was analysed for viable units and this confirmed packa-
ging quantity details. The dose was two capsules taken orally
every morning. Since this was a double-blind study and patients
were randomly allocated to receive either the probiotic treat-
ment or placebo, matching for severity of symptoms or for
other demographics was not possible.23 Patient compliance
was monitored at six time points during the 12-week trial,
with five consultations and one telephonic consult.
Dietary assessment
A registered dietitian explained and trained each participant on
the procedure for completing a prospective, three-day esti-
mated (using household food measures) dietary record. The
dietary assessment was done only at baseline (A). The impor-
tance of food recording immediately after it was eaten was
emphasised. The results were analysed by FoodFinderTM III
(https://mrc-foodfinder.software.informer.com/3.0/), a computer-
based data evaluation system for South African foods.24 The
reliability of the food records was assessed by means of a test–
retest (eight-week interval). Validity was assessed using dietary
fatty acid intake from three-day food records and comparing
with plasma fatty acid profiles.
Faecal sampling and analysis
Faecal samples were collected at three time points: baseline (A),
after eight weeks’ supplementation (B) and following a two-
week washout period (C). Samples were collected with disin-
fected plastic equipment after defecation and immediately
frozen, and kept at −20°C for up to a month before being
stored at −80°C until analysis. Not all participants provided a
stool sample at each time point (A, B and C). Total DNA was
extracted using the QIAmp DNA stool extraction mini kit
(Qiagen, Hilden GmbH, Germany) with some modifications.
The DNA concentration and integrity were determined using a
NanoDrop spectrophotometer (NanoDrop Technologies Inc,
Wilmington, DE, USA). Only samples with integrity between 1.8
and 2.2 were used.
Total Bacteroides spp., Bifidobacteria bifidum and total
Lactobacillus plantarumwere quantified using the PrimerDesign™
genesig kits (Primerdesign Ltd, Chandler’s Ford, UK) and quantitat-
ive real-time polymerase chain reaction (qPCR) amplification and
detection. These kits were designed to have the broadest detec-
tion profile possible for in vitro quantification of all Bacteroides
species and all Bifidobacterium bifidum genomes. A detection
kit was specifically developed for Lactobacillus plantarum
(Primerdesign, UK). Analysis was performed by the Biochemistry
and Microbiology Department at Nelson Mandela University.
IBS symptom severity score
The severity of GI symptoms was assessed by a validated ques-
tionnaire for use in IBS patients, the Francis Severity Score
(FSS).25 The FSS questionnaire was completed at six different
time points over the 12-week trial. The questionnaires were
self-administered.
Statistical methods
In qPCR analyses, some of the target organisms remained below
the detection limit. These values may not have been truly zero or
missing values but caused by technical limitations of the qPCR
technique. Therefore, for data analysis, the undetected
samples were given a value, which corresponded to the limit
of detection of the respective qPCR assay. The data were not
normally distributed per treatment groups (i.e. placebo vs.
probiotic) and per IBS (C-IBS vs. D-IBS) groups. Thus, the variables
were transformed with a log transformation to yield more
normally distributed data. The analyses showed that the log-
transformed data were still not normally distributed. Therefore,
the ANOVA comparisons were confirmed with Mann–Whitney
U-tests. Correlations among the continuous variables were
done with Pearson and Spearman rank correlation coefficients.
Repeated measures ANOVAs were done with the assumption
of compound symmetry (i.e. equal correlation among the FFS
responses over time). Dietary validity data were analysed using
Pearson and Spearman correlation coefficients and paired
t-tests were used to analyse reliability. The statistical analyses
were done with STATISTICA (www.statsoft.com) with a signifi-
cance level of 5%.
Results
A total of 52 IBS participants were included in this study. Demo-
graphic detail and clinical characteristics are shown in Table 1.
Participants’ mean BMIs fell either into the overweight (25.0–
29.9 kg/m2) or obese (> 30 kg/m2) categories. IBS was longstand-
ing i.e. > 5 years for most of the participants. Almost all the
participants were female (51 of 52 participants).
At baseline (A), before any probiotic intervention, Lactobacillus
plantarum profiles were significantly different between C-IBS
and D-IBS (−0.956 ± 1.239 vs. −1.700 ± 1.239; p = 0.024), with
lower counts in D-IBS. There was no significant change in
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bacterial counts after completion of the trial (B) and following
the washout period (C) between groups. Profiles for Bacteroides
spp. and Bifidobacteria bifidum were, however, not different at
baseline (A) between the C-IBS and D-IBS groups (data not
shown). The probiotic had no significant effect on bacterial pro-
files between the treatment and placebo groups from baseline
(A) to end of treatment (B) in both C-IBS and D-IBS groups
(see Table 2). There was no significant change in bacterial
counts after completion of the trial (B) and following on into
the washout period (C). When the data of only those that pro-
vided all three stool samples (n = 33) were analysed, no
significant differences were found between the C-IBS and D-
IBS groups.
Table 3 gives an overview of the participants’ nutrient intake at
baseline (A). The C-IBS group had a higher intake of energy and
macronutrients, fat, protein and carbohydrate, as well as a
slightly higher fibre intake compared with the D-IBS group,
although these differences were not significant. A small sub-
sample (C-IBS and D-IBS) of the total study group involved in
the RCT (n = 81) was used to assess validity (n = 5, 6.2% respect-
ively) and reliability (n = 6, 7.2% respectively) of the dietary
Table 1: Patient demographic and clinical characteristics (n = 52)
Factor
D-IBS C-IBS
Treatment (n = 19) Placebo (n = 9) Treatment (n = 16) Placebo (n = 8)
Average age (years) (range) 52.2 ± 16.2 (24.9–75) 42.5 ± 7.2 (31.9–51.2) 51.5 ± 9.9 (35.9–69) 49.4 ± 13.9 (33.0–72)
BMI (kg/m2) (range) 29.4 ± 7.4 (19.26–42.0) 33.07 ± 9.3 (17.19–48.9) 30.9 ± 7.2 (20.2–49.0) 27.8 ± 6.3 (21.33–40.0)
Duration of IBS symptoms (years) 7.3 ± 11.7 7.9 ± 7.1 12.7 ± 9.9 12.4 ± 8.2
No significant differences within (treatment vs. placebo control in D-IBS or C-IBS) or between groups.
D-IBS: diarrhoea-predominant irritable bowel syndrome, C-IBS: constipation-predominant irritable bowel syndrome, BMI: body mass index, IBS: irritable bowel syndrome.
Table 2: Bacterial counts in stool at baseline (A), after supplementation (B) and after washout (C)
D-IBS C-IBS
Mean count ± SE (log transformed per
nanogram DNA)
Mean count ± SE (log transformed per
nanogram DNA)
Bacteria Before (A) After (B) Washout (C) Before (A) After (B) Washout (C)
Bacteroides Treatment group 2.16 ± 2.49
(n = 15)
2.30 ± 2.85
(n = 15)
2.48 ± 2. 91
(n = 14)
3.21 ± 2.61
(n = 12)
2.69 ± 2.60
(n = 12)
3.10 ± 2.52
(n = 13)
Placebo group 1.12 ± 2.13
(n = 7)
2.16 ± 2.93
(n = 7)
1.54 ± 2.39
(n = 7)
2.49 ± 2.99
(n = 7)
2.65 ± 3.13
(n = 8)
2.74 ± 2.94
(n = 7)
Bifidobacteria Treatment group −0.69 ± 1.50
(n = 15)
−0.67 ± 1.67
(n = 17)
−0.88 ± 1.36
(n = 14)
−0.16 ± 1.66
(n = 13)
−0.53 ± 1.44
(n = 13)
−0.24 ± 1.82
(n = 12)
Placebo group −1.14 ± 1.14
(n = 7)
−1.12 ± 1.21
(n = 7)
−0.95 ± 1.59
(n = 7)
−0.37 ± 1.66
(n = 7)
−0.59 ± 1.85
(n = 8)
−0.46 ± 1.54
(n = 6)
Lactobacillus plantarum Treatment group −1.88 ± 0.00
(n = 12)
−1.14 ± 1.18
(n = 14)
−1.34 ± 0.90
(n = 13)
−0.96 ± 1.31
(n = 8)
−0.44 ± 1.21
(n = 10)
−0.89 ± 1.39
(n = 12)
Placebo group −1.34 ± 0.82
(n = 6)
−1.80 ± 0.17
(n = 6)
−1.60 ± 0.58
(n = 5)
−0.95 ± 1.27
(n = 5)
−0.96 ± 1.41
(n = 7)
−1.66 ± 0.48
(n = 5)
Mean ± SE.
No significant differences within (treatment vs. placebo control in D-IBS or C-IBS) or between groups.
D-IBS: diarrhoea-predominant irritable bowel syndrome, C-IBS: constipation-predominant irritable bowel syndrome, SE: standard error, DNA: deoxyribonucleic acid.
Table 3: Nutrient intake of participants (n = 52) at baseline (A), mean ± SD
Factor All groups D-IBS (n = 28) C-IBS (n = 24)
Energy (MJ) 7.25 ± 1.95 7.02 ± 1.76 7.53 ± 2.22
Total fat (g) 68.30 ± 22.93 66.13 ± 20.29 70.84 ± 26.29
% energy from fat 35.72 ± 6.78 36.15 ± 7.35 35.21 ± 6.05
Total protein (g) 61.04 ± 17.34 59.35 ± 17.09 63.02 ± 18.35
% energy from protein 14.88 ± 4.57 14.77 ± 3.91 15.00 ± 5.14
Total carbohydrate (g) 198.16 ± 69.29 191.49 ± 67.30 205.93 ± 71.13
% energy from carbohydrate 45.83 ± 7.34 45.64 ± 7.65 46.05 ± 7.34
Total dietary fibre (g) 14.14 ± 7.92 13.66 ± 7.69 14.72 ± 8.03
Insoluble dietary fibre (g) 4.07 ± 2.62 3.99 ± 2.59 4.16 ± 2.50
Soluble dietary fibre (g) 3.26 ± 2.41 3.28 ± 2.70 3.23 ± 1.77
Linoleic acid C18:2 (g) 16.11 ± 7.80 15.91 ± 7.67 16.34 ± 8.00
Linolenic acid C18:3 (g) 0.40 ± 0.19 0.39 ± 0.17 0.42 ± 0.20
No significant differences within (treatment vs. placebo control in D-IBS or C-IBS) or between groups.
D-IBS: diarrhoea-predominant irritable bowel syndrome, C-IBS: constipation-predominant irritable bowel syndrome, SD: standard deviation, MJ: megajoule.
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data. In the reliability testing, none of the macronutrients dif-
fered significantly from each other except that of percentage
energy intake from protein 12.33 ± 1.29 vs. 17.48 ± 3.18 g/day
(p = 0.015). Correlation coefficients for validity ranged from
0.03 to 0.69, p > 0.05.
The nutrient intake data from Table 3 were used to correlate to
the findings of the faecal microbiota. These data are presented
in Table 4 and described in detail by bacterial categories below.
Bacteroides spp.
In the combined C-IBS and D-IBS groups, Bacteroides had a sig-
nificant inverse correlation with total (r =−0.424; p = 0.019),
insoluble (r =−0.406; p = 0.023) and soluble fibre (r =−0.466;
p = 0.008). In the D-IBS group, Bacteroides inversely correlated
with total (r =−0.528; p = 0.024) and soluble dietary fibre
(r =−0.571; p = 0.013). A strong correlation was found in the
D-IBS group for percentage energy from fat and Bacteroides
(r = 0.617; p = 0.006).
Lactobacillus plantarum
A direct correlation was found for fibre fractions (total [r = 0.529;
p = 0.002], insoluble [r = 0.465; p = 0.008] and soluble fibre
[r = 0.433 p = 0.015]) and Lactobacillus plantarum in the total
group. In the D-IBS group a correlation was found for protein
intake and Lactobacillus plantarum (r = 0.487; p = 0.041). In the
C-IBS group Lactobacillus plantarum correlated well with total
dietary fibre (r = 0.584; p = 0.036).
Bifidobacteria bifidum
In the D-IBS group correlations were found for protein intake
and Bifidobacteria (r = 0.497; p = 0.036) and Bifidobacteria and
insoluble fibre (r = 0.523; p = 0.026) intake. A strong correlation
was found in the D-IBS group for linolenic acid (C18:3) intake
and Bifidobacteria (r = 0.516; p = 0.028).
There was no significant difference in symptom severity score
between the treatment and placebo groups (treatment group
259.54 ± 104.59–197.56 ± 114.74 vs. placebo group 258.71 ±
110.88–180.00 ± 96.1; p = 0.599) over the probiotic trial
period. The groups were also further divided into C-IBS vs.
placebo and D-IBS vs. placebo with no significant differences
noted. Both the treatment group and placebo group had a
significant improvement in FSS scores over the study period,
from an average of 259.27–191.71 (p < 0.0001) indicating a
large placebo effect. A strongly significant positive correlation
was found in D-IBS patients receiving placebo at time point B;
higher symptom severity score correlated with higher
Lactobacillus plantarum (r = 0.892, p < 0.05). A strongly signifi-
cant inverse correlation was seen in the C-IBS placebo group
at time point A; lower Lactobacillus plantarum counts
translated to a higher symptom severity score (r = −0.907,
p < 0.05). No other significant correlations were found
between FSS and microbiota.
Discussion
This study investigated the effects of single strain probiotic sup-
plementation, L. plantarum 299v, and nutrient intake corre-
lations on GI microbiota. No significant beneficial effects of the
probiotic were observed on severity of IBS symptoms or on GI
microbiota composition. However, nutrient intakes were
shown to have significant correlations with GI microbiota
composition. Ta
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GI microbiota alterations are increasingly being recognised as an
important factor in the pathogenesis and pathophysiology of
IBS.26 In recent years, many research groups have focused on
identifying the GI microbiota composition in IBS patients,
using modern culture-independent techniques.27 No single
deviance has been identified in IBS microbiota, but various
alterations in the bacterial composition have been character-
ised.28–31 In a recent meta-analysis, Hai-Ning et al. concluded
that there is down-regulation of bacterial colonisation including
Lactobacillus, Bifidobacterium and F. prausnitzii in IBS patients,
particularly D-IBS.32
To date there have been very few RCTs on IBS and probiotics
that have investigated possible modifications of the microbiota
by the probiotic. Knowledge on the role of microbiota modu-
lation in symptom relief is therefore limited.22,33 Nobaek et al.
examined the effect of L. plantarum DSM 9843 (299v) on
faecal microbiota and IBS symptom relief.33 There were no sig-
nificant changes in Enterobacteriaceae or sulphite-reducing
Clostridia or Enterococci counts following supplementation,
although the Enterococci count remained the same in the test
group, whereas there was a small increase in the placebo
group at the end of supplementation. Flatulence was rapidly
and significantly reduced in the test group compared with the
placebo group and abdominal pain was reduced in both
groups. Kajander et al. showed a significant improvement in
composite IBS scores with a multispecies probiotic in the treat-
ment group versus placebo group. At the same time they
demonstrated a stabilisation of the microbiota: as the microbiota
similarity index increased with the probiotic supplementation, it
decreased in the placebo group; the difference between the two
groups was significant (p = 0.0015).22 One recent study compar-
ing the composition and temporal stability of intestinal micro-
biota between IBS and healthy controls by PCR-DGGE revealed
a greater temporal instability in IBS patients (43% instability)
than in the control group (29% instability).28 These results
suggest that the pathophysiology of IBS may be associated
with temporal instability in the composition of intestinal micro-
biota. However, in our study we found that a probiotic exerted
no beneficial changes on the GI microbiota and no consistent
correlations were found between GI symptom severity and
total Bacteroides, Bifidobacterium bifidum or Lactobacillus
plantarum counts. As studies suggest, an association between
microbes and symptoms in IBS and the relative importance of
different taxa for IBS symptoms has been found to be inconsist-
ent between existing studies.26
Our study has demonstrated strong correlations between
certain dietary agents, particularly fibre, and the resulting GI
microbiota. It seems as though lower fibre diets predispose
towards an increased Bacteroides and decreased Bifidobacteria,
seen in both C-IBS and D-IBS groups. Higher fibre intake was
strongly associated with increased Lactobacillus plantarum
counts in both groups. In the D-IBS group a higher percentage
energy from fat and low fibre intake correlated to high
Bacteroides counts. These findings are in agreement with a pre-
vious study by Wu et al.34 By combining detailed nutritional
analysis and microbiome determination in 98 healthy individ-
uals, Wu et al. sought to identify nutrients that substantially
affect abundances of microbial species. They found that a
higher fat intake and lower fibre intake were associated with
the Bacteroides enterotype. The nutrient associations seen here
parallel a recent study by De Filippo et al.35 They compared
European children, who eat a typical Western diet high in
animal protein and fat, with children in Burkina Faso, who eat
high-carbohydrate diets low in animal protein. The European
microbiome was dominated by taxa typical of the Bacteroides
enterotype, whereas the African microbiome was dominated
by the Prevotella enterotype.
Recent research has highlighted that dietary intervention aimed
at decreasing fermentable carbohydrates and FODMAPS, and as
a result an improvement in IBS symptoms, also resulted in the
decrease of beneficial Bifidobacteria.36 This opens the question
as to whether probiotic supplementation is needed in addition
to dietary advice to restrict fermentable carbohydrate. Our
research has demonstrated that low fibre intake was associated
with Bifidobacteria. Dietary intake provides an attractive and
possibly the easiest therapeutic route to modulate GIT micro-
biota in IBS. If certain bacterial profiles are ultimately shown to
be causally related to disease, then long-term dietary interven-
tions may allow modulation of an individual’s bacterial profiles
to improve IBS symptoms.34
Strengths of the present study include the simultaneous assess-
ment of microbiota, IBS symptoms and dietary intake. We also
divided IBS subjects according to bowel habit sub-type. This
study is not without limitations: we quantitatively analysed
only a few major groups of bacteria that occur in the faeces
and there may have been quantitative shifts between different
factions within groups that were not detected in this analysis.
The small size of the study population may have failed to
detect other significant changes in the microbiota.
Conclusion
Lactobacillus plantarum differs between IBS phenotypes. An
eight-week course of the single stain probiotic L. plantarum
299v did not result in any significant changes in the GI microflora
or GI symptoms. Certain nutrients, especially fibre, strongly cor-
relate to certain bacterial profiles and this may provide an attrac-
tive management strategy in IBS treatment.
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